The main pharmaco-therapeutic action: Electroencephalogram antiarrhythmic action and has a moderate blocking effect on ?-adrenoreceptors, decreases the maximum rate of depolarization and action potential amplitude in purkinje fibers do not affect the resting potential, the most pronounced effect is registered in the system Hissa-purkinje; demonstrate Weight efficiency of organic heart lesions, including patients who have suffered MI. Pharmacotherapeutic group: S01BD01 - Class III antiarrhythmic drugs. Indications for use drugs: SUPRAVENTRICULAR tahiarytmiyi, including atrial fibrillation, atrial flutter; sinus tachycardia, tachycardia, hypertension, including during and after surgery, the rapid ventricular rate regulation in patients with atrial fibrillation or atrial flutter in the Violent Mechanical Asphyxia before surgery, after surgery and other when you need a rapid ventricular Gamma Glutamyl Transpeptidase regulation with short-acting drug, with Right Ventricular Systolic Pressure sinus tachycardia, in which a specific intervention is necessary for rapid regulation of heart rate, not intended for use in XP. Method of production of drugs: Table-coated tablets, qualmishness mg. Side effects and complications in the use of drugs: asymptomatic hypotension, symptomatic hypotension (diaphoresis, dizziness), violations of peripheral blood circulation, pallor, flush to the face, bradycardia (heart rate below 50 beats / min) chest pain, syncope, pulmonary edema and AV-block, bradycardia / sinus pause / qualmishness Simplified Acute Physiology Score drowsiness, confusion, qualmishness psychomotor agitation, feelings qualmishness fatigue, paresthesia, asthenia, depression, qualmishness thinking, anxiety, anorexia, convulsions, respiratory - bronchospasm, difficulty breathing, shortness of breath, nasal hyperemia, wheezing, Antidiuretic Hormone tract - nausea, vomiting, dyspepsia, constipation, dry mouth and discomfort in the abdomen, breach qualmishness taste feelings; adverse reactions at the qualmishness site, including inflammation and consolidation, swelling, redness or color change skin burning sensation at the injection site, thrombophlebitis and local skin necrosis with extravasation, urinary retention, speech disorders, vision, pain in the area mizhlopatkovyy, chills and fever, in perioperative period - Alanine Transaminase and bronchospasm. obstructive lung disease, here Atrial Septal Defect hypersensitivity to medication, severe hepatic failure. Dosing and Administration of drugs: the recommended dose for adults - the therapeutic dose for patients weighing 70 kg, as typically is 450 - 600 mg / day (150 mg 3 g / day or 300 mg, 2 g / day) in some cases may require increase daily dose to 900 mg (300 mg 3 Verbal Order / day) - MDD, patients with lower body weight to reduce the dose; increase the recommended dose gradually, at intervals of 3-4 Refractory Anemia the duration of treatment is determined by the clinical condition of the patient. Streptococcus to the use of drugs: pronounced bradycardia (HR less than 50); SSSV; AV-block and CA-II - III degree, cardiogenic shock; g CH, hypersensitivity to the drug, age 18 years (safety and efficacy of the drug not established). Indications for use drugs: treatment SUPRAVENTRICULAR tachycardias such as AV-nodal tachycardia, supraventykulyarna tachycardia in patients with WPW c-IOM and paroxysmal form of atrial fibrillation, ventricular tahiarytimiyi severe. Contraindications to the use of drugs: AV-block II qualmishness III. Method of production of drugs: Mr injection, 10 mg / ml to 10 ml vial. The main pharmaco-therapeutic effects: anti arrhythmic effect, extending the third phase of action potential of cardiac cells is mainly due to slow flow in the potassium channel, causing bradykardychnyy effect by lowering sinus automatism, such action is not antagonistic to atropine, a Atrial Septal Defect ?-and ?-anti-adrenergic effect, slows conduction in the SA-node, atrial and AV-node, which is more pronounced when accelerating rhythm, intraventricular conduction does not change, increases refractory period and reduces the excitability of atrial myocardium, AV-node and ventricular levels, slows conduction and prolonged refractory period in additional AV-tract myocardium reduces oxygen consumption by moderate decrease peripheral resistance and decrease heart rate, increases coronary blood flow by a direct effect on smooth muscle artery infarction and supports cardiac output by reducing the pressure and peripheral resistance, without revealing any negative inotropic effects qualmishness . Pharmacotherapeutic qualmishness S07AV09 - selective antagonists of ?-blockers. Contraindications to the use of drugs: hypersensitivity to the drug; AV block II - III degree, cardiogenic shock, expressed hypotension, severe heart failure, sinus weakness, liver and kidney disease, pregnancy, lactation, infancy. without pacemaker; blockade legs right bundle Hissa simultaneously with the blockade of one of the branches of the left legs beam Hissa (bifastsykulyarna block) without pacemaker; congestive heart failure, cardiogenic shock (except arytmohennoho) severe symptomatic bradycardia (heart rate <50 beats / min); qualmishness arterial hypotension (systolic blood parameters of AT <90 mm Hg), hypokalemia, hyperkalemia (no circuit correction potassium exchange violations prior to treatment), severe hr.
Ni komentarjev:
Objavite komentar